Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,450.00
Bid: 12,448.00
Ask: 12,452.00
Change: -60.00 (-0.48%)
Spread: 4.00 (0.032%)
Open: 12,556.00
High: 12,562.00
Low: 12,420.00
Prev. Close: 12,510.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: "Moment To Celebrate" As Astra Vaccine Approved In UK

Wed, 30th Dec 2020 08:12

(Alliance News) - AstraZeneca said its Covid-19 vaccine has been approved for emergency supply in the UK, with the first doses being released on Wednesday so that vaccinations may begin early in the New Year.

The FTSE 100 pharmaceutical firm said it aims to supply millions of doses in the first quarter as part of an agreement with the UK government to supply up to 100 million doses in total.

The vaccine, developed together with Oxford University, was authorised by the UK Medicines & Healthcare Products Regulatory Agency, recommending two doses administered with an interval of between four and 12 weeks. Clinical trials showed the vaccine to be safe and effective at preventing symptomatic Covid-19, with no severe cases and no hospitalisations more than 14 days after the second dose.

"Today is an important day for millions of people in the UK who will get access to this new vaccine. It has been shown to be effective, well-tolerated, simple to administer and is supplied by AstraZeneca at no profit," AstraZeneca Chief Executive Pascal Soriot said on Wednesday.

Added UK Secretary of State for Health & Social Care Matt Hancock: "This is a moment to celebrate British innovation - not only are we responsible for discovering the first treatment to reduce mortality for Covid-19, this vaccine will be made available to some of the poorest regions of the world at a low cost, helping protect countless people from this awful disease."

The AstraZeneca vaccine is the second to be approved in the UK. The Pfizer/Biontech vaccine was approved earlier in December.

AstraZeneca shares were up 1.5% early Wednesday.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: up 0.1% at 6,607.56

----------

Hang Seng: up 2.2% at 27,141.97

Nikkei 225: closed down 0.5% at 27,444.17

DJIA: closed down 68.30 points, 0.2%, at 30,335.67

S&P 500: closed down 0.2% at 3,727.04

----------

GBP: up at USD1.3537 (USD1.3509)

EUR: up at USD1.2269 (USD1.2246)

Gold: down at USD1,879.34 per ounce (USD1,882.29)

Oil (Brent): up at USD51.36 a barrel (USD51.16)

(changes since previous London equities close)

----------

ECONOMICS AND GENERAL

----------

Wednesday's Key Economic Events still to come

0930 CET EU EuroCOIN indicator of euro area economic activity

0830 EST US goods trade balance

1000 EST US pending home sales index

1030 EST US EIA weekly petroleum status report

----------

More areas in England will be placed under the country's toughest coronavirus restrictions, Health Secretary Hancock is expected to tell the Commons on Wednesday, PA reports. Pressure mounted on the UK government to act as hospitals across England warned of increasing strains on services due to Covid-19 patient numbers, which have reached their highest levels during the pandemic, while 51,135 further cases and 414 deaths were reported on Tuesday. Local authorities in Essex have declared a "major incident" as the number of coronavirus cases threatens to overwhelm health services in the county. Ambulances were seen queueing outside hospitals including the Royal London Hospital in Whitechapel and Queen's Hospital in Romford, both in east London, and Queen Elizabeth Hospital, Birmingham, on Tuesday, and a junior doctor in the capital said his his hospital was "aggressively overstretched" by Covid-19 patients.

----------

UK Prime Minister Boris Johnson is expected to decide imminently on whether to keep secondary schools shut in order to try to reduce coronavirus transmission. Johnson is set to chair a key meeting on Wednesday looking at delaying the reopening of secondary schools, according to the Daily Telegraph. It comes amid growing concerns from unions and scientists about the spread of the virus following the discovery of its much more transmissible variant. London Mayor Sadiq Khan said he did not want to see schools closed or the education of children disrupted. Labour has called for UK Education Secretary Gavin Williamson to make a statement to MPs on Wednesday on the plan for schools and colleges.

----------

The UK will "open a new chapter in our national story", Johnson has claimed as MPs prepare to vote on his Brexit deal. On Wednesday, Parliament will be recalled to give its ruling on the trade agreement reached more than four years after the In/Out referendum in 2016. The EU (Future Relationship) Bill is expected to clear the Commons with the Conservatives and the majority of Labour MPs set to support it, although the SNP, the DUP, Plaid Cymru, the SDLP, Alliance and the Liberal Democrats have all indicated they will not vote for it.

----------

UK house prices surged in December to post their fastest growth in six years, according to the house price index from mortgage lender Nationwide. House prices jumped 7.3% year-on-year in December, accelerating from rises of 6.5% in November and 5.8% in October to achieve the highest annual growth rate since 2014. Month-on-month, house prices rose 0.8%, a touch slower than the 0.9% growth seen in November. The average UK house price stood at GBP230,920 in December versus GBP229,721 in November. House prices ended the year 5.3% above the level prevailing in March, when the pandemic struck the UK.

----------

BROKER RATING CHANGES

----------

none reported

----------

COMPANIES - FTSE 250

----------

Energean said it has agreed with Kerogen Investments, an affiliate of Kerogen Capital, for the acquisition of Kerogen's 30% shareholding in Energean Israel, which would result in Energean owning 100% of Israel unit share capital. A total consideration of between USD380 million and USD405 million, the Mediterranean-focussed gas exploration and production company said. Energean said the acquisition adds 2P reserves of 29.5 billion cubic metres of gas and 30 million barrels of liquids, representing 219 million barrels of oil equivalent in total, to the company. Taking a 100% interest in Energean Israel will enable Energean to fully control its capital structure, it said, enhancing its ability to maximise total shareholder returns.

----------

COMPANIES - MAIN MARKET AND AIM

----------

Exploration and development company Indus Gas reported a decline in pretax profit for the six months to the end of September to USD20.9 million from USD26.1 million a year earlier, as adjusted revenue declined to USD23.2 million from USD27.7 million. The company said its administrative expenses rose to USD586,360 from USD303,970 year-on-year. "While the pandemic has presented unprecedented operational challenges, the company remains focused on executing our strategy to maximize value for all of our stakeholders," said Chair Peter Cockburn.

----------

Wednesday's Shareholder Meetings

Quiz PLC - AGM

Corcel PLC - AGM

Nu-Oil & Gas PLC - AGM

Plexus Holdings PLC - AGM

Secure Property Development & Investment PLC - AGM

Eco (Atlantic) Oil & Gas Ltd - AGM

Gresham Technologies PLC - GM re incentive plan and remuneration policy

eEnergy Group PLC - AGM

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
23 Oct 2023 08:45

TOP NEWS: AstraZeneca says Enhertu approved by European Commission

(Alliance News) - AstraZeneca PLC on Monday said its Enhertu treatment has been approved by the European Commission to treat adult lung cancer patients.

Read more
23 Oct 2023 07:46

LONDON BRIEFING: Keller expects higher profit; Upland rejects approach

(Alliance News) - Stocks in London are set to open slightly higher on Monday, as risk sentiment improves after a difficult period for markets last week.

Read more
18 Oct 2023 09:04

AstraZeneca drug Solaris approved in China as NMOSD treatment

(Alliance News) - AstraZeneca PLC on Wednesday announced that eculizumab, whose brand name is Solaris, has been approved in China to treat patients with neuromyelitis optica spectrum disorder

Read more
17 Oct 2023 12:06

LONDON MARKET MIDDAY: European markets uneasy but FTSE 100 outperforms

(Alliance News) - London's FTSE 100 higher was higher around midday, though it was defensive stocks such as utilities and pharmaceuticals which led the charge, suggesting there is still lingering discomfort in markets amid tensions in the Middle East.

Read more
16 Oct 2023 08:34

TOP NEWS: AstraZeneca's cancer drug gets priority review from US FDA

(Alliance News) - AstraZeneca PLC on Monday said that its new drug application for Tagrisso has been granted priority review in the US, after trial results extended progression-free survival.

Read more
4 Oct 2023 12:14

IN BRIEF: AstraZeneca's Forxiga drug shows positive results in trial

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows "clinically meaningful" improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes.

Read more
3 Oct 2023 16:55

LONDON MARKET CLOSE: Stocks red as rate rise fears continue to grow

(Alliance News) - Stocks in London were lower at the close on Tuesday after unexpectedly strong US job openings data added to fears that interest rates in the world's largest economy will stay higher for longer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
3 Oct 2023 08:36

TOP NEWS: AstraZeneca settles Nexium and Prilosec litigation

(Alliance News) - AstraZeneca PLC on Tuesday said it has settled legal matters involving its Nexium acid reflux and Prilosec heartburn products, parting with USD425 million.

Read more
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.